MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Portfolio Pulse from
MIRA Pharmaceuticals has received approval to initiate a Phase 1 clinical trial for Ketamir-2, a novel oral ketamine analog for neuropathic pain. The trial will be conducted in Israel, with recruitment starting in Q1 2025.
March 04, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals has announced the approval and initiation of a Phase 1 clinical trial for Ketamir-2, targeting neuropathic pain. This marks a significant step in their drug development pipeline.
The approval and initiation of a Phase 1 clinical trial is a positive development for MIRA Pharmaceuticals, indicating progress in their drug development efforts. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100